Efficacy and Safety of Peginterferon Alfa‐2a (40KD) in Children With Chronic Hepatitis B: The PEG‐B‐ACTIVE Study

Stefan Wirth, Hongfei Zhang, Winita Hardikar, Kathleen B. Schwarz, Etienne Sokal, Weibo Yang, Huimin Fan, Vyacheslav Morozov, Qing Mao, Hong Deng, Yang Huang, Lei Yang, Nicolas Frey, Clare Nasmyth‐Miller, Vedran Pavlovic, Cynthia Wat – 24 April 2018 – Children with chronic hepatitis B (CHB) represent an area of unmet medical need, attributed to increased lifetime risk of CHB sequelae and limited therapeutic options compared with adult CHB patients. The PEG‐B‐ACTIVE (NCT01519960) phase III study evaluated peginterferon (PegIFN) alfa‐2a treatment in children aged 3 to <18 years with CHB.

Molecular profiling of postreperfusion milieu determines acute kidney injury after liver transplantation: A prospective study

Carlo Pulitano, Phong Ho, Deborah Verran, Charbel Sandroussi, David Joseph, David G. Bowen, Geoffrey W. McCaughan, Michael Crawford, Nicholas Shackel – 23 April 2018 – Acute kidney injury (AKI) after liver transplantation (LT) is a common event, but its pathogenesis remains unclear. The aim of this prospective study is to investigate the potential relationship between postreperfusion gene expression, serum mediators, and the onset of AKI after LT. Sixty‐five consecutive patients undergoing LT were included in the study.

Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7‐Year Longitudinal Study

Gyuri Kim, Seung‐Eun Lee, You‐Bin Lee, Ji Eun Jun, Jiyeon Ahn, Ji Cheol Bae, Sang‐Man Jin, Kyu Yeon Hur, Jae Hwan Jee, Moon‐Kyu Lee, Jae Hyeon Kim – 20 April 2018 – Nonalcoholic fatty liver disease (NAFLD) has been associated with relative skeletal muscle mass in several cross‐sectional studies. We explored the effects of relative skeletal muscle mass and changes in relative muscle mass over time on the development of incident NAFLD or the resolution of baseline NAFLD in a large, longitudinal, population‐based 7‐year cohort study.

Subscribe to